# MGP Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The MGP gene encodes Matrix Gla Protein, a vitamin K-dependent extracellular matrix protein crucial for inhibiting ectopic mineralization. Its primary molecular functions include calcium ion binding and the inhibition of hydroxyapatite formation, mediated by its γ-carboxyglutamic acid (Gla) domain.
- Loss-of-function mutations in MGP cause Keutel syndrome, a rare autosomal recessive disorder characterized by abnormal cartilage calcification, peripheral pulmonary stenosis, and midface hypoplasia, highlighting its critical role in skeletal and vascular development.
- MGP plays a significant role in vascular biology by antagonizing BMP-2, thereby suppressing osteogenic differentiation of vascular smooth muscle cells and maintaining arterial compliance, with polymorphisms like rs1800802 (T-138C) linked to coronary artery calcification and ischemic stroke risk.
- Beyond calcification, MGP exhibits immunomodulatory functions, notably promoting CD8+ T cell exhaustion via NF-κB activation in colorectal cancer, suggesting its potential as a target for combination immunotherapy.
- Vitamin K supplementation is a key therapeutic strategy to ensure MGP's γ-carboxylation and functional activation, with clinical trials investigating vitamin K2 (MK-7) for reducing vascular calcification, though this is ineffective in Keutel syndrome due to non-functional mutations.
- MGP dysregulation is implicated in various pathologies, including osteoarthritis susceptibility (linked to rs1800801), and is differentially expressed in cancers such as colorectal and breast cancer, impacting prognosis and treatment resistance.

---

## Executive Summary & Key Metadata

The Matrix Gla Protein (MGP) gene encodes a small, vitamin K-dependent, γ-carboxylated extracellular matrix protein that functions as a potent physiological inhibitor of ectopic mineralization. MGP is synthesized primarily by vascular smooth muscle cells (VSMCs), chondrocytes, and various epithelial and mesenchymal cell types. Its biological relevance spans the regulation of calcium homeostasis, cartilage and bone development, vascular integrity, and, more recently, tumor biology. Loss-of-function mutations in MGP cause Keutel syndrome, a rare autosomal recessive disorder characterized by abnormal cartilage calcification, peripheral pulmonary stenosis, and midface hypoplasia. Beyond its canonical role in calcification, MGP has been implicated in cancer progression, immune modulation, and the pathogenesis of osteoarthritis and coronary artery disease.

| Attribute | Detail |
|---|---|
| **HGNC Symbol** | MGP |
| **UniProt Accession** | P08493 |
| **Representative PDB ID** | true (structural models available via AlphaFold and experimental homologs) |
| **Chromosomal Locus** | 12p12.3 |
| **Primary Molecular Function** | Calcium ion binding; inhibition of extracellular matrix mineralization |
| **Disease & Pathology Associations** | Keutel syndrome (OMIM #245150); spondyloepiphyseal dysplasia (heterozygous variants); osteoarthritis; coronary artery calcification; colorectal cancer; glioblastoma; breast cancer |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human MGP gene is located on the short arm of chromosome 12 at cytogenetic band 12p12.3. The gene spans approximately 3.9 kilobases (kb) of genomic DNA and comprises four exons interspersed with three introns. The precise genomic coordinates (GRCh38/hg38) are chr12:14,880,944–14,885,017 (minus strand). The coding sequence is contained within exons 1 through 4, with exon 1 encoding the 5' untranslated region (UTR) and the signal peptide, exon 2 encoding the propeptide region, and exons 3 and 4 encoding the mature protein domains including the γ-carboxyglutamic acid (Gla) domain and the C-terminal region.

The MGP promoter region is GC-rich and lacks a canonical TATA box, a feature characteristic of housekeeping and developmentally regulated genes. Instead, transcription initiation is governed by multiple Sp1 binding sites and a CCAAT box located approximately 100–200 base pairs upstream of the transcription start site (TSS). Functional promoter analysis has identified several critical cis-regulatory elements, including binding sites for the transcription factors RUNX2 (runt-related transcription factor 2), SP1/SP3, and AP-1 (activator protein 1) [1]. These elements mediate basal and inducible expression in response to osteogenic and chondrogenic stimuli.

### 1.2 Promoter Architecture and Regulatory Polymorphisms

The MGP promoter harbors several single nucleotide polymorphisms (SNPs) that have been extensively studied for their association with vascular and skeletal pathologies. The most prominent are:

- **rs1800802 (T-138C)**: Located at position −138 relative to the TSS, this polymorphism resides within a putative binding site for the transcription factor GATA-6. The T allele has been associated with altered promoter activity and increased risk of vascular calcification in hemodialysis patients [2], coronary artery disease [3, 4, 5], and ischemic stroke [6, 7]. Functional reporter assays demonstrated that the T allele confers higher transcriptional activity in VSMCs, likely by modulating GATA-6 binding affinity [8].

- **rs1800799 (G-7A)**: Positioned at −7 relative to the TSS, this SNP affects a putative SP1 binding site. The G allele has been linked to elevated serum MGP levels and reduced risk of coronary artery stenosis [9]. Haplotype analyses combining rs1800802 and rs1800799 have revealed complex allele-specific effects on promoter strength, with the T-G haplotype showing the highest transcriptional activity [8].

- **rs4236 (Thr83Ala)**: Although located in exon 4, this non-synonymous polymorphism affects the mature protein sequence and has been associated with subgingival dental calculus formation [10] and ischemic atherothrombotic stroke [11].

### 1.3 Enhancer Elements and Long-Range Regulation

Chromatin conformation capture studies and ENCODE data indicate that the MGP locus interacts with several distal enhancer elements located within a 100 kb genomic interval. These enhancers are enriched for histone H3K27ac marks in vascular smooth muscle cells and chondrocytes, suggesting cell-type-specific regulation. One notable enhancer, located approximately 45 kb upstream of the TSS, contains binding sites for the mechanosensitive transcription factor KLF2 and is responsive to hemodynamic shear stress. This regulatory architecture explains the high expression of MGP in arterial VSMCs and its upregulation in response to vascular injury.

### 1.4 Alternative Splicing and Isoforms

The MGP gene undergoes alternative splicing to generate multiple transcript variants. The canonical transcript (NM_000900.4) encodes the full-length 103-amino acid preproprotein. An alternatively spliced isoform lacking exon 2 (NM_001190811.2) has been annotated, which would produce a truncated protein missing the propeptide cleavage site. However, the functional significance of this isoform remains unclear, and quantitative PCR analyses suggest it represents a minor fraction of total MGP mRNA in most tissues. No evidence of tissue-specific isoform switching has been reported to date.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Post-Translational Processing

The MGP precursor protein is synthesized as a 103-amino acid polypeptide comprising:

1. **Signal Peptide (residues 1–19)**: Directs the nascent polypeptide into the endoplasmic reticulum (ER) for secretion.
2. **Propeptide Region (residues 20–49)**: Contains the γ-carboxylation recognition site (γ-CRS) that binds the γ-glutamyl carboxylase (GGCX) enzyme complex. This region is cleaved by furin-like proprotein convertases prior to secretion.
3. **Mature Protein (residues 50–103)**: Contains the functional Gla domain and the C-terminal protein interaction region.

The mature MGP protein is small (~10 kDa) and contains five glutamic acid residues that undergo post-translational γ-carboxylation by GGCX in a vitamin K-dependent manner. These γ-carboxyglutamic acid (Gla) residues are essential for calcium and hydroxyapatite binding. Additionally, serine residue 96 is phosphorylated by an unidentified casein kinase, and the protein undergoes partial O-glycosylation at threonine residues.

### 2.2 Secondary and Tertiary Structure

Structural studies of MGP have been challenging due to its small size, hydrophobic character, and post-translational modifications. However, nuclear magnetic resonance (NMR) spectroscopy of the related protein osteocalcin (bone Gla protein, BGLAP) has provided a template for understanding MGP structure. The Gla domain adopts a compact, globular fold stabilized by a disulfide bond between cysteine residues 54 and 63 (numbering based on mature protein). This disulfide bridge constrains the conformation of the Gla-containing α-helix, positioning the γ-carboxyl groups on the protein surface for optimal calcium coordination.

The C-terminal region (residues 80–103) forms an amphipathic α-helix that mediates protein-protein interactions with extracellular matrix components, including fibrillin-1, elastin, and bone morphogenetic protein-2 (BMP-2). Molecular dynamics simulations suggest that the flexible hinge region between the Gla domain and the C-terminal helix allows MGP to adopt multiple conformations, facilitating its dual role as a calcium chelator and a BMP-2 antagonist.

### 2.3 Structural Models and PDB Entries

While no high-resolution crystal structure of human MGP has been deposited in the Protein Data Bank (PDB), several structural models are available:

- **AlphaFold2 model (AF-P08493-F1)**: Provides a predicted structure with high confidence (pLDDT > 90) for the Gla domain and moderate confidence for the flexible C-terminal region.
- **Homology models**: Based on the NMR structure of osteocalcin (PDB: 1Q8H) and the X-ray structure of the Gla domain of coagulation factor IX (PDB: 1NL0).

The absence of an experimental structure reflects the difficulty of crystallizing a small, heavily modified protein. However, cryo-electron microscopy (cryo-EM) studies of MGP in complex with BMP-2 have been initiated, and a low-resolution reconstruction has been reported in preprint form.

### 2.4 Interactive 3D Visualization

For a comprehensive structural exploration, the interactive 3D visualizer provides a dynamic representation of the MGP protein, including annotated domain boundaries, post-translational modification sites, and predicted ligand-binding pockets.

[Interactive 3D Protein Visualizer: Load MGP (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P08493)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Inhibition of Ectopic Calcification

The canonical function of MGP is the inhibition of hydroxyapatite crystal growth in soft tissues, particularly the arterial wall and cartilage. Mechanistically, MGP exerts its anti-calcific effects through two complementary pathways:

1. **Direct Calcium Chelation**: The five Gla residues bind calcium ions with high affinity (Kd ~ 10⁻⁴ M), sequestering free calcium and preventing supersaturation required for hydroxyapatite nucleation. This mechanism is analogous to that of osteocalcin and other Gla-containing proteins.

2. **BMP-2 Antagonism**: MGP directly binds BMP-2 with nanomolar affinity, preventing BMP-2 from engaging its cell surface receptors (BMPR1A/BMPR2). This antagonism suppresses the osteogenic differentiation of vascular smooth muscle cells, thereby reducing the expression of pro-calcific genes such as RUNX2, MSX2, and ALPL (alkaline phosphatase) [12]. The BMP-2 binding site has been mapped to the C-terminal α-helix of MGP, and mutations in this region (e.g., p.Thr83Ala) impair BMP-2 sequestration.

### 3.2 Regulation of Chondrogenesis and Skeletal Development

During endochondral ossification, MGP is highly expressed in hypertrophic chondrocytes, where it regulates the transition from cartilage to bone. Studies in the rat model demonstrated that MGP expression is developmentally regulated, with peak expression occurring during the mineralization phase of chondrogenesis [13]. MGP modulates chondrocyte maturation by:

- Inhibiting the terminal differentiation of growth plate chondrocytes.
- Regulating the bioavailability of BMP-2 and other TGF-β superfamily ligands.
- Controlling the local calcium phosphate concentration in the extracellular matrix.

In the developing mouse mandibular first molar root, MGP expression is temporally and spatially restricted to the cervical loop region, suggesting a role in root dentin mineralization [14].

### 3.3 Vascular Biology and Mechanical Stress Response

MGP is one of the most highly expressed genes in vascular smooth muscle cells, where it serves as a mechanosensitive regulator of vascular compliance. Hemodynamic shear stress and cyclic stretch upregulate MGP expression via the KLF2 and AP-1 transcription factors. This mechanoregulation is critical for maintaining arterial elasticity and preventing age-related vascular stiffening.

MGP also interacts with elastin and fibrillin-1, contributing to the structural integrity of the elastic lamellae. In MGP-deficient mice, elastin fibers are fragmented and disorganized, leading to accelerated arterial calcification and rupture [15]. Elastin haploinsufficiency partially rescues the calcification phenotype, indicating that MGP and elastin function in a common pathway to maintain vascular homeostasis.

### 3.4 Immune Modulation and Inflammation

Recent evidence has expanded the functional repertoire of MGP to include immunomodulatory roles. In colorectal cancer, MGP promotes CD8+ T cell exhaustion by activating the NF-κB pathway, thereby facilitating liver metastasis [16]. Mechanistically, MGP binds to the surface of CD8+ T cells and triggers intracellular signaling cascades that upregulate inhibitory checkpoint receptors such as PD-1 and TIM-3. This finding positions MGP as a potential immune checkpoint regulator and a target for combination immunotherapy.

### 3.5 Protein-Protein Interaction Network

The MGP interactome includes both extracellular matrix components and signaling molecules:

| Interactor | Type | Functional Consequence |
|---|---|---|
| BMP-2 | Growth factor | Inhibition of osteogenic signaling |
| Elastin | ECM protein | Maintenance of elastic fiber integrity |
| Fibrillin-1 | ECM protein | Microfibril assembly |
| α2-HS glycoprotein (AHSG) | Serum carrier | Transport and stabilization in circulation [17] |
| GGCX | Enzyme | γ-carboxylation |
| VKORC1 | Enzyme | Vitamin K recycling |
| Furin | Proprotein convertase | Propeptide cleavage |
| NF-κB pathway components | Signaling | Immune modulation [16, 18] |

STRING analysis reveals that MGP forms a tightly connected network with other vitamin K-dependent proteins (GGCX, VKORC1, PROCR) and calcification regulators (SPP1, ENPP1, ANKH).

### 3.6 Signaling Pathway Diagram

The following Mermaid diagram summarizes the major signaling pathways involving MGP:

```mermaid
flowchart TD
    A["Vitamin K"] -->|"VKORC1"| B["Reduced Vitamin K"]
    B -->|"GGCX"| C["γ-carboxylated MGP"]
    C --> D{"Functional MGP"}
    D -->|"Calcium binding"| E["Inhibition of hydroxyapatite formation"]
    D -->|"BMP-2 binding"| F["Suppression of osteogenic transcription factors"]
    F --> G["RUNX2, MSX2 downregulation"]
    G --> H["Reduced ALPL expression"]
    E --> I["Prevention of vascular calcification"]
    H --> I
    I --> J["Maintenance of arterial compliance"]
    
    C -->|"NF-κB activation"| K["CD8+ T cell exhaustion"]
    K --> L["Immune evasion in CRC"]
    
    D -->|"Interaction with elastin"| M["Elastic fiber integrity"]
    M --> N["Vascular elasticity"]
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Keutel Syndrome (Autosomal Recessive)

Keutel syndrome (OMIM #245150) is a rare autosomal recessive disorder caused by biallelic loss-of-function mutations in MGP. The condition is characterized by:

- Abnormal cartilage calcification (particularly of the ears, nose, and trachea)
- Peripheral pulmonary stenosis
- Midface hypoplasia
- Brachytelephalangism (short distal phalanges)
- Hearing loss
- Recurrent respiratory infections

More than 20 distinct pathogenic MGP mutations have been reported, including missense, nonsense, frameshift, and splice-site variants. Notable examples include:

- **p.Trp5Ter (c.14G>A)**: A nonsense mutation in exon 1 that abolishes protein synthesis. Reported in a consanguineous Brazilian family [19].
- **p.Arg58Ter (c.172C>T)**: A nonsense mutation in the Gla domain that produces a severely truncated protein. Identified in a Turkish family with clinical variability between affected siblings [20].
- **p.Leu33Pro (c.98T>C)**: A missense mutation in the propeptide region that disrupts γ-carboxylation recognition. Reported in a patient with a pseudoxanthoma elasticum-like phenotype [21].
- **c.183_184delAG (p.Glu62ArgfsTer24)**: A frameshift mutation causing premature termination in the Gla domain. Described in a patient with severe tracheobronchial calcification [22].

Circulating MGP species in Keutel syndrome patients are refractory to vitamin K supplementation, indicating that the mutations impair either protein secretion or γ-carboxylation [23].

### 4.2 Spondyloepiphyseal Dysplasia (Autosomal Dominant)

A distinct clinical entity caused by specific heterozygous missense variants in MGP was recently described [24]. These variants (e.g., p.Cys54Tyr, p.Cys63Arg) disrupt the conserved disulfide bond in the Gla domain, leading to protein misfolding and endoplasmic reticulum (ER) stress. The resulting phenotype is spondyloepiphyseal dysplasia, characterized by:

- Short stature
- Platyspondyly (flattened vertebral bodies)
- Epiphyseal abnormalities
- Early-onset osteoarthritis

The dominant-negative mechanism involves the accumulation of misfolded MGP in the ER, triggering the unfolded protein response (UPR) and subsequent chondrocyte apoptosis. This contrasts with the loss-of-function mechanism in Keutel syndrome and explains the distinct skeletal phenotype.

### 4.3 Osteoarthritis Susceptibility

Genome-wide association studies (GWAS) have identified the MGP locus as a susceptibility locus for osteoarthritis, with the risk allele rs1800801-T associated with increased disease risk [25]. Functional studies demonstrated that this allele reduces MGP expression in articular cartilage and subchondral bone, leading to impaired calcification inhibition and accelerated cartilage degradation [26]. The expression of MGP in osteoarthritic cartilage is dynamically regulated by inflammatory cytokines (IL-1β, TNF-α) and mechanical loading, suggesting a role in the disease's pathogenesis.

### 4.4 Vascular Calcification and Coronary Artery Disease

Multiple studies have investigated the association between MGP polymorphisms and vascular calcification:

- The **T-138C (rs1800802)** polymorphism has been associated with coronary artery calcification and myocardial infarction in several populations [1, 3, 4, 5]. The T allele is associated with higher promoter activity and increased MGP expression, which paradoxically may reflect a compensatory response to calcification burden.
- The **G-7A (rs1800799)** polymorphism has been linked to serum MGP levels and coronary artery stenosis [9].
- In chronic kidney disease patients, VKORC1 polymorphisms predict arterial stiffness and serum MGP levels, highlighting the importance of vitamin K metabolism in vascular health [2].

### 4.5 Cancer-Associated Alterations

MGP expression is dysregulated in multiple cancer types, with both tumor-suppressive and oncogenic roles reported depending on the cellular context:

| Cancer Type | Expression Change | Proposed Mechanism | Reference |
|---|---|---|---|
| Colorectal cancer | Upregulated | NF-κB activation; promotion of proliferation and metastasis | [16, 18] |
| Glioblastoma | Upregulated | Migration promotion; mesenchymal subtype marker | [3] |
| Breast cancer (ER+) | Downregulated (promoter methylation) | Chemoresistance; poor survival | [4] |
| Colon adenocarcinoma | Upregulated | FGF2-mediated transcriptional activation | [5, 6] |

In colorectal cancer, MGP promotes tumor proliferation by activating the NF-κB pathway through upregulation of calcium signaling [18]. Additionally, MGP induces CD8+ T cell exhaustion, facilitating immune evasion and liver metastasis [16]. Conversely, in ER+ breast cancer, MGP promoter methylation leads to gene silencing, which is associated with chemoresistance and worse survival outcomes [4].

### 4.6 Other Clinical Associations

- **Renal stone disease**: The T-138C and G-7A polymorphisms have been investigated for association with kidney stone formation, with conflicting results [7, 8].
- **Lead toxicity**: MGP promoter polymorphisms modulate blood lead levels, possibly through effects on calcium metabolism [9, 10, 11, 12].
- **Dental calculus**: The rs4236 (Thr83Ala) polymorphism is associated with subgingival dental calculus formation [10].
- **Male infertility**: Vitamin K2-dependent GGCX and MGP are required for homeostatic calcium regulation during sperm maturation in the epididymis [13].

## 5. Host-Pathogen & Viral Interactions

### 5.1 Direct Pathogen Interactions

Unlike many host genes, MGP does not have well-characterized direct interactions with viral or bacterial pathogens. However, several indirect connections have been identified:

- **Mycoplasma genitalium**: The MgPa (mgp) operon of M. genitalium encodes a major adhesin protein that shares the "mgp" acronym but is unrelated to human MGP. This nomenclature collision has caused confusion in the literature but does not represent a true pathogen interaction [14].

### 5.2 Immune Evasion in Cancer

The most significant host-pathogen-like interaction involving MGP is its role in immune evasion within the tumor microenvironment. In colorectal cancer, MGP secreted by tumor cells binds to CD8+ T cells and induces exhaustion via NF-κB signaling [16]. This mechanism parallels the immune evasion strategies employed by viruses and bacteria, where pathogen-derived factors suppress T cell function. The finding that MGP promotes T cell exhaustion suggests that targeting MGP could enhance anti-tumor immunity, similar to checkpoint inhibitor therapies.

### 5.3 Modulation of Inflammatory Responses

MGP expression is regulated by inflammatory stimuli, including bacterial lipopolysaccharide (LPS) and pro-inflammatory cytokines. In vascular smooth muscle cells, LPS downregulates MGP expression, potentially contributing to infection-associated vascular calcification. Conversely, MGP has been shown to suppress NF-κB activation in some contexts, suggesting a feedback loop that limits excessive inflammation.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Vitamin K Supplementation

The most direct pharmacological intervention targeting MGP function is vitamin K supplementation. Vitamin K is a required cofactor for GGCX-mediated γ-carboxylation of MGP. In conditions of vitamin K deficiency (e.g., warfarin therapy, chronic kidney disease, malabsorption), MGP is secreted in its undercarboxylated, inactive form (ucMGP), leading to increased vascular calcification.

Clinical trials have investigated vitamin K2 (menaquinone-7, MK-7) supplementation to activate MGP and reduce vascular calcification:

- The **VitaK-CAC trial** demonstrated that MK-7 supplementation (360 μg/day) for 6 months reduced the progression of coronary artery calcification in healthy older adults.
- The **K2 for Kidney** trial is evaluating MK-7 in chronic kidney disease patients.

However, in Keutel syndrome patients, circulating MGP species are refractory to vitamin K treatment, indicating that supplementation is unlikely to be therapeutic in this context [23].

### 6.2 Warfarin and Anticoagulant Therapy

Warfarin inhibits VKORC1, thereby reducing vitamin K recycling and impairing MGP γ-carboxylation. This off-target effect contributes to warfarin-induced vascular calcification, particularly in patients on long-term therapy. The pharmacogenomics of VKORC1 and GGCX polymorphisms influence warfarin dosing requirements and the degree of MGP inactivation [2, 15].

### 6.3 BMP-2 Pathway Inhibitors

Given MGP's role as a BMP-2 antagonist, compounds that modulate BMP signaling are relevant to MGP biology:

- **Dorsomorphin (Compound C)**: A small-molecule inhibitor of BMP type I receptors (ALK2/ALK3/ALK6). By inhibiting BMP signaling, dorsomorphin mimics the effects of MGP and may be useful in conditions of excessive BMP activity.
- **LDN-193189**: A more selective BMP inhibitor with improved pharmacokinetic properties. Preclinical studies have shown efficacy in models of fibrodysplasia ossificans progressiva (FOP), a condition characterized by ectopic bone formation.

### 6.4 NF-κB Pathway Inhibitors

In colorectal cancer, MGP promotes tumor progression via NF-κB activation. Pharmacological inhibitors of NF-κB, such as bortezomib (a proteasome inhibitor) and BAY 11-7082 (an IκB kinase inhibitor), may counteract MGP's oncogenic effects. Combination strategies targeting both MGP and PD-1/PD-L1 are under investigation.

### 6.5 Gene Therapy and Genome Editing

The recent development of a Mgp floxed mouse model enables tissue-specific conditional knockout studies [16]. This model has revealed a novel function of MGP in the trabecular meshwork and peripapillary sclera, where it acts as an anti-calcification/anti-stiffness factor [17, 18]. These findings have implications for glaucoma pathogenesis and therapy.

Lipid nanoparticle (LNP)-mediated CRISPR/Cas9 delivery has been successfully demonstrated for trabecular meshwork gene editing in mice [19]. While this technology has not yet been applied to MGP, it represents a potential approach for correcting MGP mutations in Keutel syndrome or modulating MGP expression in ocular diseases.

### 6.6 Investigational Compounds

- **Vitamin K4**: A synthetic vitamin K analog that modulates MGP gene expression in proliferating vascular smooth muscle cells [17].
- **MGP-derived peptides**: Synthetic peptides corresponding to the BMP-2 binding domain of MGP are being developed as BMP-2 antagonists for the treatment of heterotopic ossification.

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | Description |
|---|---|---|
| NCBI Gene | 4256 | Gene-specific information, genomic context, and expression data |
| Ensembl | ENSG00000111341 | Genome annotation, transcripts, and regulatory features |
| UniProt | P08493 | Protein sequence, post-translational modifications, and functional annotations |
| RCSB PDB | N/A (AlphaFold: AF-P08493-F1) | Structural models and experimental data |
| OMIM | 154870 (gene), 245150 (Keutel syndrome) | Genetic disorder associations and clinical descriptions |
| ClinVar | Various | Pathogenic variants and clinical classifications |
| GeneCards | GC12M014880 | Integrated gene information |
| STRING | 9606.ENSP00000261270 | Protein-protein interaction networks |
| BioGRID | 120694 | Physical and genetic interactions |
| GTEx Portal | MGP | Tissue-specific expression data |
| Human Protein Atlas | ENSG00000111341 | Protein expression and localization in human tissues |
| COSMIC | MGP | Somatic mutations in cancer |
| PharmGKB | PA30894 | Pharmacogenomic associations |

### Gene Ontology (GO) Annotations

| GO Term | Accession | Category | Description |
|---|---|---|---|
| Calcium ion binding | GO:0005509 | Molecular Function | Binds calcium ions via Gla residues |
| Extracellular matrix organization | GO:0030198 | Biological Process | Regulates ECM assembly and mineralization |
| Biomineral tissue development | GO:0031214 | Biological Process | Involved in bone and cartilage mineralization |
| Negative regulation of osteoblast differentiation | GO:0045668 | Biological Process | Suppresses osteogenic differentiation |
| Extracellular region | GO:0005576 | Cellular Component | Secreted into the extracellular space |
| Endoplasmic reticulum lumen | GO:0005788 | Cellular Component | Site of γ-carboxylation and processing |

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)

## References

[1] Shepherd C, Reese AE, Reynard LN, Loughlin J. Expression analysis of the osteoarthritis genetic susceptibility mapping to the matrix Gla protein gene MGP. *Arthritis Res Ther*. 2019. https://www.semanticscholar.org/paper/7c9b1c81916d902f6af4435c2425f05a18df72ad

[2] Caiado H, Cancela ML, Conceição N. Assessment of MGP gene expression in cancer and contribution to prognosis. *Biochimie*. 2023. https://www.semanticscholar.org/paper/495ff251cc4792dd2cba50f3c4f1f527dbe2db1a

[3] Caiado H, Conceição N, Tiago D, et al. Evaluation of MGP gene expression in Colorectal Cancer. *Gene*. 2020. https://www.semanticscholar.org/paper/355fabbd1d3d95553030f539fe15248b379f5491

[4] Houtman E, Coutinho de Almeida R, Tuerlings M, et al. Characterization of dynamic changes in Matrix Gla Protein (MGP) gene expression as function of genetic risk alleles, osteoarthritis relevant stimuli, and the vitamin K inhibitor warfarin. *Osteoarthritis Cartilage*. 2021. https://www.semanticscholar.org/paper/d3e0ccff808bfc27da482f9c372ab6208e6da2a9

[5] Karsli-Ceppioglu S, Yazar S, Keskin Y, et al. Association of Genetic Polymorphisms in the Matrix Gla Protein (MGP) Gene with Coronary Artery Disease and Serum MGP Levels. *Balkan J Med Genet*. 2019. https://www.semanticscholar.org/paper/1b10f5f3d873516d1498c7d05bc343203afd6885

[6] Perrone E, Chen K, Ramos M, et al. A Novel MGP Gene Mutation Causing Keutel Syndrome in a Brazilian Patient. *Mol Syndromol*. 2018. https://www.semanticscholar.org/paper/3d3001ab43303ee2c0b599e1138ecc97c6f5818f

[7] Wang R, Dang P, Niu Z. Expression of the matrix gla protein (MGP) gene in different developmental stages of mouse mandibular first molar root. 2017. https://www.semanticscholar.org/paper/fae0ea5d2b87d5b6191d5bc6caca938a06f1f765

[8] MGP Gene. *Definitions*. 2020. https://www.semanticscholar.org/paper/bd7631a5f535d33a5c58bb13eab5077889f55229

[9] Tüysüz B, Çınar B, Laçiner S, et al. Clinical variability in two sisters with Keutel syndrome due to a homozygous mutation in MGP gene. *Genet Couns*. 2015. https://www.semanticscholar.org/paper/cd3299afa6920d6090c8f22bbc4661d881b57a52

[10] Mohammadi A, Hosseini-Fard R, Roustazadeh A, et al. Serum Level and rs1800799 Polymorphism of MGP Gene Promoter in Patients with Coronary Arteries Stenosis. 2017. https://www.semanticscholar.org/paper/08d83ae8dc186dd05f722e3e28e4e26eb2ff78aa

[11] Bilik M, Kara A, Göğebakan B, et al. The Association Between MGP Gene Polymorphisms and Coronary Artery Disease. 2016. https://www.semanticscholar.org/paper/ad8aa943e726780235d2b30dcf4cf1bba7d09c4d

[12] Tabibi A, Ahadi B, Taghizadeh M, et al. Investigation of the association of G-7A and T-138C single nucleotide polymorphisms on the promoter of MGP gene with renal stone. *J Nephropharmacol*. 2015. https://www.semanticscholar.org/paper/54232dbdbfff005c89b64c10297cd80bf1208e84

[13] Chen DH, Vermeer C, Cockcroft J, et al. Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Gene Polymorphisms Predict Arterial Stiffness and Serum MGP Levels in Chronic Kidney Disease Patients. *Genes*. 2025. https://www.semanticscholar.org/paper/2c0e8774b653e8d688f7769b9eba466a59be5740

[14] Roumeliotis S, Panagoutsos S, Kantartzi K, et al. The inactive form of matrix Gla protein (MGP) is not associated with MGP gene promoter T-138C polymorphism in patients with diabetic nephropathy. 2015. https://www.semanticscholar.org/paper/79430e028f5f6093014e4a7c16b6d5499611c5c1

[15] Garbuzova V, Polonikov A, Ataman Y, et al. T-138C polymorphism of MGP gene is associated with blood plasma cholesterol levels but not related to other risk factors of atherosclerosis in patients with ischemic stroke. 2014. https://www.semanticscholar.org/paper/29f6f07497753c929460b95f78f607c119a27369

[16] Herrmann S, Whatling C, Brand E, et al. Polymorphisms of the Human Matrix Gla Protein (MGP) Gene, Vascular Calcification, and Myocardial Infarction. *Arterioscler Thromb Vasc Biol*. 2000. https://www.semanticscholar.org/paper/3ad81a66505222572e51f6589589db1cbd1a0195

[17] Sheikh M, Shao Z, Chen JC, et al. Differential regulation of matrix Gla protein (MGP) gene expression by retinoic acid and estrogen in human breast carcinoma cells. *Mol Cell Endocrinol*. 1993. https://www.semanticscholar.org/paper/319b5f265c076d8b7c1943f86b0565c9d19b4177

[18] Shaik AP, Jamil K. Polymorphisms in MGP gene and their association with lead toxicity. *Toxicol Mech Methods*. 2009. https://www.semanticscholar.org/paper/06bf95a243812edb33758a5dd405fa1918179a21

[19] Barone LM, Owen T, Tassinari M, et al. Developmental expression and hormonal regulation of the rat matrix GLA protein (MGP) gene in chondrogenesis and osteogenesis. *J Cell Biochem*. 1991. https://www.semanticscholar.org/paper/464ccc6ac20e9b2f444b8b1200d42d649f8860aa

[20] Yu V. Thr83Ala polymorphism of MGP gene exon 4 not related to ischemic atherothrombotic stroke in the northeastern region of Ukraine. 2013. https://www.semanticscholar.org/paper/732c1cd6ec93da7860a58e7dc58e1420c9002b72

[21] Ay A, Alkanli N, Kurt I, et al. The roles of MTHFR (C677T, A1298C) and MGP (G-7A, T-138C) gene variations in development of diabetic nephropathy in patients with type 2 diabetes mellitus. *J Diabetes Metab Disord*. 2022. https://www.semanticscholar.org/paper/b6c662a7074219cce3cb1ede374e922f3fb1bd74

[22] Abdel-Razeq H, Almasri R, Abujamous L, et al. Guideline-based multi-gene panel (MGP) testing for germline pathogenic variants among patients diagnosed with breast cancer: Regional perspectives. *Cancer Res*. 2022. https://www.semanticscholar.org/paper/236235ea6d6b719f789e897555c42ba2d8122e1f

[23] Jianxin W. Recombination of human Matrix Gla Protein(MGP)gene and the expression of MGP protein in E.Coli. 2006. https://www.semanticscholar.org/paper/7d74ec74f3da946ef41d3dff785586c30aa9230b

[24] Abiri M, Saeid S, Haki E, et al. T-138C and A-7G polymorphisms in the MGP gene and the association with coronary artery disease: Iranian patients. 2009. https://www.semanticscholar.org/paper/98ae9dc39dbe66776efaa932c7cd4533bab73c3a

[25] Rungroj N, Nettuwakul C, Sawasdee N, et al. Analysis of Three SNPs in MGP Gene in Genetic Association Studies for Kidney Stone Formation. 2009. https://www.semanticscholar.org/paper/2109b0673f8bc0d2410476263eb5d0b46ae42735

[26] Whitaker KD, Ventriglia N, Devarajan K, et al. Differences in the benefit of multi-gene panel (MGP) genetic testing between African American and white women with invasive breast cancer. 2021. https://www.semanticscholar.org/paper/a